Kyruus vs Moderna

Side-by-side comparison of AI visibility scores, market position, and capabilities

Moderna leads in AI visibility (90 vs 72)
Kyruus logo

Kyruus

LeaderHealthcare

Provider Data Management & Care Access

Kyruus Health connects 500K+ providers across 1,400 hospitals and 100+ health plan brands; launched AI provider matching on AWS Bedrock with Claude 3.5 Sonnet; partnered with Healthgrades and Google Cloud in 2025.

AI VisibilityBeta
Overall Score
B72
Category Rank
#104 of 596
AI Consensus
86%
Trend
stable
Per Platform
ChatGPT
73
Perplexity
74
Gemini
68

About

Kyruus Health is the leading care access platform in the United States, connecting patients and health plan members to the right providers through a combination of provider data management, intelligent search, and AI-powered matching. The platform serves over 500,000 providers across 1,400 hospitals, 550 medical groups, and 100+ health plan brands — making it the de facto infrastructure for provider directory management and patient-facing provider search across much of the U.S. healthcare system. Kyruus Health''s solutions include provider directory management, consumer-facing search experiences, appointment scheduling enablement, and payer-side member engagement tools.

Full profile
Moderna logo

Moderna

LeaderHealthcare Tech

Enterprise

mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.

AI VisibilityBeta
Overall Score
A90
Category Rank
#2 of 596
AI Consensus
83%
Trend
stable
Per Platform
ChatGPT
92
Perplexity
93
Gemini
89

About

Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.

Full profile

AI Visibility Head-to-Head

72
Overall Score
90
#104
Category Rank
#2
86
AI Consensus
83
stable
Trend
stable
73
ChatGPT
92
74
Perplexity
93
68
Gemini
89
73
Claude
96
72
Grok
95

Key Details

Category
Provider Data Management & Care Access
Enterprise
Tier
Leader
Leader
Entity Type
brand
company

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.